通过调节三阴性乳腺癌细胞中的瘤免疫微环境,卡达摩宁具有抗癌作用
Patricia Mendonca1,2, Sukhmandeep Kaur1, Bhonesa Kirpal1
1Division of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University Tallahassee, FL 32307, The United States.
American journal of cancer research
|January 13, 2025
概括
卡达蒙尼是一种天然化合物,通过调节瘤免疫微环境 (TIME) 和抑制PD-L1表达,在三阴性乳腺癌 (TNBC) 中克服免疫疗法耐药性方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤免疫微环境 (TIME) 对癌症进展和免疫治疗反应至关重要.
- 免疫检查点抑制剂,如PD-1/PD-L1疗法,面临由于新兴耐药性的挑战.
- 需要新的化合物来增强三阴性乳腺癌 (TNBC) 免疫治疗的有效性.
研究的目的:
- 调查天然化合物卡达摩宁对TNBC中PD-L1表达和TIME调节的影响.
- 探索卡达蒙尼在TNBC中克服免疫疗法耐药性的潜力.
主要方法:
- 使用了两个不同的TNBC细胞系:MDA-MB-231和MDA-MB-468.
- 用卡达蒙尼治疗细胞并分析其对PD-L1,JAK1,STAT3,Nrf2,MUC1,NF-κB1,NF-κB2和CCL2水平的影响.
- 评估卡达蒙宁对时间的调制.
主要成果:
- 卡达摩宁抑制了PD-L1表达,并在MDA-231细胞中降低了JAK1/STAT3;在MDA-468细胞中增加了JAK1.
- 卡达摩宁在两种细胞系中都提高了Nrf2的调节,并在MDA-231细胞中降低了MUC1,MDA-468细胞中降低了NF-κB1/2和NF-κB1.
- 卡达蒙尼显著降低了CCL2水平,可能减少巨细胞透,增强T细胞透.
结论:
- 卡达摩宁通过影响TNBC中的关键信号通路和炎症标志物来调节TIME.
- 卡达蒙因降低PD-L1和CCL2的能力表明,它有可能逆转对PD-1/PD-L1免疫疗法的耐药性.
- 卡达摩宁作为TNBC的辅助疗法具有前景,增强免疫疗法结果.
相关概念视频
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
01:45Positive Regulator Molecules
105.7K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
105.7K
02:17The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:10Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K